ceftazidime

Contraindicated in:

Hypersensitivity to cephalosporins;
Serious hypersensitivity to penicillins.

Use Cautiously in:

Renal impairment (↓ dosing/↑ dosing interval recommended if CCr ≤50 mL/min);
History of GI disease, especially colitis;
Lactation: Direct drug effects and modification of bowel flora may occur in the nursing infant;
Geri: Dose adjustment may be necessary due to age-related ↓ in renal function.

Adv. Reactions/Side Effects ⬆ ⬇

Derm: rash, pruritus, urticaria

GI: CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), abdominal pain, diarrhea, nausea, vomiting

Hemat: bleeding, blood dyscrasias, hemolytic anemia

Local: pain at IM site, phlebitis at IV site

Neuro: encephalopathy, SEIZURES(HIGH DOSES IN PATIENTS WITH RENAL IMPAIRMENT)

Misc: fever, HYPERSENSITIVITY REACTIONS(INCLUDING ANAPHYLAXIS) , superinfection

Interactions ⬆ ⬇

Drug-drug:

Concurrent use of loop diuretics or nephrotoxic agents includingaminoglycosides may ↑ risk of nephrotoxicity.
Bactericidal activity ↓ by chloramphenicol.

Availability ⬆ ⬇

(Generic available)

Powder for injection: 1 g/vial; 2 g/vial; 6 g/vial
Premixed infusion: 1 g/50 mL; 2 g/50 mL

Route/Dosage ⬆ ⬇

IM IV (Adults and Children ≥12 yr): Pneumonia and skin/skin structure infections: 500 mg–1 g every 8 hr. Bone and joint infections: 2 g every 12 hr.Severe and life-threatening infections: 2 g every 8 hr.Complicated urinary tract infections: 500 mg every 8–12 hr.Uncomplicated urinary tract infections: 250 mg every 12 hr.Cystic fibrosis lung infection caused by Pseudomonas aeruginosa: 30–50 mg/kg every 8 hr (max daily dose = 6 g).
IM IV (Children 1 mo–12 yr): 100–150 mg/kg/day divided every 8 hr (maximum dose:6 g/day).
IM IV (Neonates ≤4 wk): 50 mg/kg every 8–12 hr.

Renal Impairment

IM IV (Adults ): CCr 31–50 mL/min: 1 g every 12 hr; CCr 16–30 mL/min: 1 g every 24 hr; CCr 6–15 mL/min: 500 mg every 24 hr; CCr <5 mL/min: 500 mg every 48 hr.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Inhibits bacterial cell wall synthesis.

Therapeutic effects:

Bactericidal action against susceptible bacteria.

Spectrum:

Similar to that of second-generation cephalosporins, but activity against staphylococci is less, while activity against gram-negative pathogens (particularly Pseudomonas aeruginosa) is greater, even for organisms resistant to first- and second-generation agents.
Notable is increased action against:
- Citrobacter,
- Enterobacter,
- Haemophilus influenzae(including β-lactamase-producing strains),
- Escherichia coli,
- Klebsiella pneumoniae,
- Neisseria meningitidis,
- Proteus,
- Providencia,
- Pseudomonas aeruginosa,
- Serratia,
- Moraxella catarrhalis.
Not active against methicillin-resistant staphylococci or enterococci.

Classifications ⬆ ⬇

Therapeutic Classification: anti-infectives

Pharmacologic Classification: third generation cephalosporins

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed following IM administration; IV administration results in complete bioavailability.

Distribution: Widely distributed. Crosses the placenta; enters breast milk in low concentrations. CSF penetration better than with first- and second-generation agents.

Protein Binding: 17%.

Metabolism/Excretion: 80–90% excreted unchanged in urine.

Half-Life: Neonates: 2.2–4.7 hr; Adults: 2 hr (↑ in renal impairment).

Time/Action Profile ⬆ ⬇

ROUTE	ONSET	PEAK	DURATION
IV	rapid	end of infusion	6–12 hr

Patient/Family Teaching ⬆ ⬇

Advise patient to report signs of superinfection (furry overgrowth on the tongue, vaginal itching or discharge, loose or foul-smelling stools) and allergy.
Instruct patient to notify health care professional if fever and diarrhea develop, especially if stool contains blood, pus, or mucus. Advise patient not to treat diarrhea without consulting health care professional.
Rep: Advise females of reproductive potential to notify health professional if pregnancy is planned or suspected or if breastfeeding. Monitor infants exposed to ceftazidime for GI disturbances (thrush or diarrhea).

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

0409- Hospira, Inc.
- 0409-5082- TAZICEF
  - 0409-5082-16- 25 VIAL in 1 CARTON (0409-5082-16) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL (0409-5082-11)

0409- Hospira, Inc.
- 0409-5084- TAZICEF
  - 0409-5084-11- 10 VIAL in 1 CARTON (0409-5084-11) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL (0409-5084-13)

0409- Hospira, Inc.
- 0409-5086- TAZICEF
  - 0409-5086-11- 10 VIAL, PHARMACY BULK PACKAGE in 1 CARTON (0409-5086-11) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, PHARMACY BULK PACKAGE (0409-5086-13)

0409- Hospira, Inc.
- 0409-5092- TAZICEF
  - 0409-5092-16- 25 VIAL, PATENT DELIVERY SYSTEM in 1 TRAY (0409-5092-16) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, PATENT DELIVERY SYSTEM (0409-5092-11)

0409- Hospira, Inc.
- 0409-5093- TAZICEF
  - 0409-5093-11- 10 VIAL, PATENT DELIVERY SYSTEM in 1 TRAY (0409-5093-11) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, PATENT DELIVERY SYSTEM (0409-5093-14)

10402- Antibioticos do Brasil Ltda
- 10402-013-
  - 10402-013-05- 5000 g in 1 BAG (10402-013-05)

25021- Sagent Pharmaceuticals
- 25021-127- Ceftazidime
  - 25021-127-20- 25 VIAL in 1 CARTON (25021-127-20) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL

25021- Sagent Pharmaceuticals
- 25021-128- Ceftazidime
  - 25021-128-50- 10 VIAL in 1 CARTON (25021-128-50) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL

25021- Sagent Pharmaceuticals
- 25021-129- Ceftazidime
  - 25021-129-99- 6 BOTTLE in 1 CARTON (25021-129-99) / 30 mL in 1 BOTTLE

44567- WG Critical Care, LLC
- 44567-235- Ceftazidime
  - 44567-235-25- 25 VIAL in 1 CARTON (44567-235-25) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL

44567- WG Critical Care, LLC
- 44567-236- Ceftazidime
  - 44567-236-10- 10 VIAL in 1 CARTON (44567-236-10) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL

44567- WG Critical Care, LLC
- 44567-237- Ceftazidime
  - 44567-237-06- 6 VIAL in 1 CARTON (44567-237-06) / 100 mL in 1 VIAL

52946- ACS Dobfar S.p.A
- 52946-0924-
  - 52946-0924-0- 5 kg in 1 BAG (52946-0924-0)

82608- PURE AND CURE HEALTHCARE PRIVATE LIMITED
- 82608-010-
  - 82608-010-01- 1 CONTAINER in 1 BOX (82608-010-01) / 10 kg in 1 CONTAINER

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇